$Palantir Technologies Inc.(PLTR)$
The FDA's guidelines to replace animal testing suggest that preclinical data can be provided based on AI models and organoid experiment data. The obvious beneficiaries in this round are AI pharmaceuticals like Recursion (RXRX). Palantir (PLTR), which had previously stated its involvement, is now expanding its commercial scope. It can now fully lay out contracts outside of government and military sectors, such as the major American supermarket chains like Walmart (WMT), large pharmaceutical companies under the current situation, and a considerable number of manufacturing companies. Although it's challenging, it's still necessary to plan ahead. If the situation in the US continues to deteriorate, it will be much more difficult to expand later.
Comments